Aviceda Therapeutics has released topline results from its phase 2b study, SIGLEC, evaluating AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
TORONTO, CANADA – Cynapsus Therapeutics Inc. (CTH: TSX-V) (CYNAF: OTCQX), a specialty pharmaceutical company, today announced positive data from its recently completed CTH-104 healthy volunteer pilot ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Study Overview: UroGen Pharma is ...
CHILLICOTHE - A feasibility study regarding the potential extension of sanitary sewer service north along the Ohio 104 corridor is moving forward, with an eye toward possible development advantages ...
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today successful completion of the validation study for its Preecludia™ rule ...
NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, today announced a collaboration with ...
LAVAL, Québec, Dec. 02, 2021 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced positive results for GTX-104 based on its interim ...
Aviceda Therapeutics ("the Company" or "Aviceda"), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback